Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Segmentation by Category (Pharmaceutical, and Biopharmaceutical Industry); by Therapeutic Application (Infectious Diseases, Oncology, Metabolic Disorders, Cardiovascular Disorders, and Others); by End-User (Pharmaceutical & Biopharmaceutical Companies, Medical Device Companies, and Academic Institutes); by Service Type (Pharmaceutical CMO, and Pharmaceutical CRO)-Demand Analysis & Opportunity Outlook 2020-2030
-
Product Code:
RP-ID-10352351 -
Published Date:
21 Oct 2022 -
Region:
Country
-
Pages:
243 -
Category:
Healthcare & Pharmaceuticals -
Publisher:
Pub-ID-54
Impact Analysis on the Growth of Market
Inflation and Looming Recession to Haunt Businesses:
In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022.
....
The Research Report is Updated with 2022 Base Year, 2023 Estimated year and Forecast till 2035 with Market Insights.
With the dip in global production, the GDP has contracted in 2020 and impacted the market across the world. Upon placing a Sample Request, you will receive an updated report with 2022 as base year, 2023 as estimated year and forecast to 2035. This will have market drivers, recovery rate in the market, insights and competitive analysis.
Market Overview:
Translate Report
Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Highlights Over 2020 - 2030
The Europe pharmaceutical contract development and manufacturing organization (CDMO) market is estimated to garner a revenue of USD 39920.2 Million by the end of 2030, by growing at a CAGR of 6.7% over the forecast period, i.e., 2021 – 2030. Moreover, in the year 2020, the market in the region generated a revenue of USD 21133.3 Million. The growth of the market can be attributed primarily to the growing prevalence of different types of chronic diseases in the region, such as cancer, diabetes, and cardiovascular diseases amongst others, and therefore the need for advanced pharmaceutical drugs that can help in the treatment of these deadly diseases. According to the statistics by the European Commission, in the year 2018, there were 1.68 Million deaths in the European Union due to the diseases of the circulatory system. Moreover, according to the statistics by the World Health Organization (WHO), the European region registered about 60 Million people above the age of 25 years that had diabetes. Additionally, the statistics also stated that between the year 2005 and 2030, the number of deaths caused due to diabetes in the region is estimated to double.
-Market.jpg)
CLICK TO DOWNLOAD SAMPLE REPORT
The growth of the Europe pharmaceutical contract development and manufacturing organization (CDMO) market can also be attributed to the growing advancements in medical research and the need for high potency active pharmaceutical ingredients (HPAPI). Besides this, the rise in demand for antibody-drug conjugates and the need amongst the pharmaceutical companies for developing advanced novel drugs are some of the additional factors projected to contribute to the growth of the market in the coming years.
Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Regional Synopsis
The Europe pharmaceutical contract development and manufacturing organization (CDMO) market is segmented on the basis if countries into Germany, United Kingdom, France, Italy, Spain, Russia, and the Rest of Europe. The market in Italy is anticipated to garner the largest revenue of USD 8942.1 Million by the end of 2030, up from a revenue of USD 4860.7 Million in the year 2020. The growth of the market in the nation can primarily be attributed to the presence of several pharmaceutical companies who are producers of active pharmaceutical ingredients (APIs), as well as for the presence of an established network of pharmaceutical manufacturing companies who deal with different types of pharmaceutical drugs. According to the statistics by the International Trade Administration (ITA) of the United States Department of Commerce, in the year 2018, there were 641 biotechnology companies in Italy, of which, 320 were red biotech companies. Moreover, the total turnover of the biotechnology companies in the nation registered USD 13666 Million in the same year, while investments in R&D by these companies amounted to USD 2428 Million in that year.
Growth Drivers and Challenges Impacting the Growth of the Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market
Growth Drivers
-
Growing Demand for High Potency Active Pharmaceutical Ingredients (HPAPI) Amongst Pharmaceutical Organizations
-
Rising Number of Medical Research and Development Activities
-
Increasing Prevalence of Chronic Diseases in the Region
Challenges
-
Stringent Government Regulations
-
Loss of Intellectual Property
Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Segmentation Synopsis
The Europe pharmaceutical contract development and manufacturing organization (CDMO) market is segmented by category into pharmaceutical industry and biopharmaceutical industry, out of which, the pharmaceutical industry is anticipated to garner the largest revenue by the end of 2030 and also grow with a CAGR of 6.5% during the forecast period. By therapeutic application, the market is segmented into infectious diseases, oncology, metabolic disorders, cardiovascular disorders, central nervous system, pulmonary disorders, gastrointestinal disorders, and other therapeutic applications. Out of these, the oncology segment is anticipated to garner the largest revenue of USD 10609.8 Million by the end of 2030, up from a revenue of USD 5441.8 Million in the year 2020. By end-user, the market is segmented into pharmaceutical & biopharmaceutical companies, medical device companies, and academic institutes. Out of these, the pharmaceutical & biopharmaceutical companies segment is anticipated to garner the largest revenue of USD 27756.1 Million by the end of 2030, up from a revenue of USD 14771.1 Million in the year 2020. By service type, the market is segmented into pharmaceutical contract manufacturing organization (CMO), and pharmaceutical contract research organization (CRO), out of which, the pharmaceutical CMO segment is projected to garner the largest revenue by the end of 2030 and also grow with the highest CAGR of 6.9% during the forecast period.
Key Companies Dominating the Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the Europe pharmaceutical contract development and manufacturing organization (CDMO) market that are included in our report are Hangzhou Tigermed Consulting Co., Ltd, ICON plc, IQVIA Inc., LSK Global Pharma Services Co., Ltd., Parexel International Corporation, PPD Inc., Almac Group, Quanticate International Limited, Samsung Biologics, Syneos Health, Wuxi Apptec Co., Ltd., Delpharm Holding, Evonik Industries AG, Siegfried Holding AG, Aenova Group, Baxter International, Inc., Boehringer Ingelheim International GmbH, Catalent, Inc., Famar Group, Jubilant Pharmova Limited, Lonza, CMIC HOLDINGS Co., LTD., Labcorp Drug Development, Thermo Fisher Scientific Inc., Pfizer Inc., Recipharm AB, Vetter Pharma-Fertigung GmbH & Co. KG, Charles River Laboratories International, Inc., and others.
Latest Developments in the Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market:
-
July 2nd, 2021: Parexel International Corporation announced that it has executed a definitive merger agreement with EQT Private Equity and Goldman Sachs Asset Management. Under the agreement, Parexel will be acquired by both these companies for a value worth USD 8.5 Billion.
-
February 24th, 2021: ICON plc announced that it has entered into a definitive agreement with PRA Health Sciences, Inc. for the acquisition of the latter in a cash and stock transaction valued at around USD 12 Billion.
Key Reasons to Buy Our Report
-
The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis and challenges that impact the market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
-
We provide customized reports as per the clients’ requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.
.
FREQUENTLY ASKED QUESTIONS
The growing demand for high potency active pharmaceutical ingredients (HPAPI) amongst pharmaceutical organizations and the rising number of medical research and development activities are anticipated to drive the market growth.
The market is anticipated to attain a CAGR of 6.7% over the forecast period, i.e., 2021-2030.
The stringent government regulations, and the loss of intellectual property are estimated to hamper the market growth.
The market in Italy is anticipated to garner the largest revenue of USD 8942.1 Million by the end of 2030 and provide more business opportunities in the future.
The major players in the market are Hangzhou Tigermed Consulting Co., Ltd, ICON plc, IQVIA Inc., LSK Global Pharma Services Co., Ltd., Parexel International Corporation, and others.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by category, therapeutic application, end-user, service type, and by country.
The pharmaceutical & biopharmaceutical companies segment is anticipated to garner the largest revenue of USD 27756.1 Million by the end of 2030 and display significant growth opportunities.
1. Market Definition and Research Methodology
1.1. Market Definition and Segmentation
1.2.Assumptions and Acronyms
1.3.Research Objective
1.4.Research Methodology
2. Executive Summary
3. Value Chain Analysis
4. Market Dynamics
4.1.Drivers
4.2. Trends
5. Key Market Opportunities
6. Major Roadblocks for the Market Growth
7. Regulatory & Standards Landscape
8. Industry Risk Analysis
9. COVID-19 Impact on Market (2020-2030)
10. Competitive Positioning
11. Competitive Landscape
11.1. Hangzhou Tigermed Consulting Co., Ltd
11.2. ICON plc
11.3. IQVIA Inc.
11.4. LSK Global Pharma Services Co., Ltd.
11.5. Parexel International Corporation
11.6. PPD Inc.
11.7. Almac Group
11.8. Quanticate International Limited
11.9. Samsung Biologics
11.10. Syneos Health
11.11. Wuxi Apptec Co., Ltd.
11.12. Delpharm Holding
11.13. Evonik Industries AG
11.14. Siegfried Holding AG
11.15. Aenova Group
11.16. Baxter International, Inc.
11.17. Boehringer Ingelheim International GmbH
11.18. Catalent, Inc.
11.19. Famar Group
11.20. Jubilant Pharmova Limited
11.21. Lonza
11.22. CMIC HOLDINGS Co., LTD.
11.23. Labcorp Drug Development
11.24. Thermo Fisher Scientific Inc.
11.25. Pfizer Inc.
11.26. Recipharm AB
11.27. Vetter Pharma-Fertigung GmbH & Co. KG
11.28. Charles River Laboratories International, Inc.
12.Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market
12.1. Market Overview – Market Size (2020–2030)
12.2. Market segmentation by:
12.2.1. Category
12.2.1.1. Pharmaceutical Industry, 2020-2030 (in USD Million)
12.2.1.2. Biopharmaceutical Industry, 2020-2030 (in USD Million)
12.2.2. Therapeutic Application
12.2.2.1. Infectious Diseases, 2020-2030 (in USD Million)
12.2.2.2. Oncology, 2020-2030 (in USD Million)
12.2.2.3. Metabolic Disorders, 2020-2030 (in USD Million)
12.2.2.4. Cardiovascular Disorders, 2020-2030 (in USD Million)
12.2.2.5. Central Nervous System, 2020-2030 (in USD Million)
12.2.2.6. Pulmonary Disorders, 2020-2030 (in USD Million)
12.2.2.7. Gastrointestinal Disorders, 2020-2030 (in USD Million)
12.2.2.8. Other Therapeutic Applications, 2020-2030 (in USD Million)
12.2.3. End-user
12.2.3.1. Pharmaceutical & Biopharmaceutical Companies, 2020-2030 (in USD Million)
12.2.3.2. Medical Device Companies, 2020-2030 (in USD Million)
12.2.3.3. Academic Institutes, 2020-2030 (in USD Million)
12.2.4. Service Type
12.2.4.1. Pharmaceutical Contract Manufacturing Organization (CMO), 2020-2030 (in USD Million)
12.2.4.1.1. Active Pharmaceutical Ingredients, 2020-2030 (in USD Million)
12.2.4.1.1.1. Branded API Manufacturing, 2020-2030 (in USD Million)
12.2.4.1.1.2. Generic API Manufacturing, 2020-2030 (in USD Million)
12.2.4.1.2. Finished Dosage Formulations (FDF), 2020-2030 (in USD Million)
12.2.4.1.2.1. Solid Dosage, 2020-2030 (in USD Million)
12.2.4.1.2.2. Oral Liquids, 2020-2030 (in USD Million)
12.2.4.1.2.3. Parenteral/Injectables, 2020-2030 (in USD Million)
12.2.4.1.2.4. Other FDFs, 2020-2030 (in USD Million)
12.2.4.1.3. Secondary Packaging, 2020-2030 (in USD Million)
12.2.4.2. Pharmaceutical Contract Research Organization (CRO), 2020-2030 (in USD Million)
12.2.4.2.1. CRO for Pre-clinical Development, 2020-2030 (in USD Million)
12.2.4.2.1.1. CRO for Phase I Trials, 2020-2030 (in USD Million)
12.2.4.2.1.2. CRO for Phase II Trials, 2020-2030 (in USD Million)
12.2.4.2.1.3. CRO for Phase III Trials, 2020-2030 (in USD Million)
12.2.4.2.1.4. CRO for Phase IV Trials, 2020-2030 (in USD Million)
12.2.4.2.2. Laboratory Services, 2020-2030 (in USD Million)
12.2.4.2.3. Consulting Services, 2020-2030 (in USD Million)
12.2.4.2.4. Data Management Services, 2020-2030 (in USD Million)
12.2.5. Country
12.2.5.1. Germany, 2020-2030 (in USD Million)
12.2.5.2. United Kingdom, 2020-2030 (in USD Million)
12.2.5.3. France, 2020-2030 (in USD Million)
12.2.5.4. Italy, 2020-2030 (in USD Million)
12.2.5.5. Spain, 2020-2030 (in USD Million)
12.2.5.6. Russia, 2020-2030 (in USD Million)
12.2.5.7. Rest of Europe, 2020-2030 (in USD Million)
13.Germany Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market
13.1. Market Overview – Market Size (2020–2030)
13.2. Market segmentation by:
13.2.1. Category
13.2.1.1. Pharmaceutical Industry, 2020-2030 (in USD Million)
13.2.1.2. Biopharmaceutical Industry, 2020-2030 (in USD Million)
13.2.2. Therapeutic Application
13.2.2.1. Infectious Diseases, 2020-2030 (in USD Million)
13.2.2.2. Oncology, 2020-2030 (in USD Million)
13.2.2.3. Metabolic Disorders, 2020-2030 (in USD Million)
13.2.2.4. Cardiovascular Disorders, 2020-2030 (in USD Million)
13.2.2.5. Central Nervous System, 2020-2030 (in USD Million)
13.2.2.6. Pulmonary Disorders, 2020-2030 (in USD Million)
13.2.2.7. Gastrointestinal Disorders, 2020-2030 (in USD Million)
13.2.2.8. Other Therapeutic Applications, 2020-2030 (in USD Million)
13.2.3. End-user
13.2.3.1. Pharmaceutical & Biopharmaceutical Companies, 2020-2030 (in USD Million)
13.2.3.2. Medical Device Companies, 2020-2030 (in USD Million)
13.2.3.3. Academic Institutes, 2020-2030 (in USD Million)
13.2.4. Service Type
13.2.4.1. Pharmaceutical Contract Manufacturing Organization (CMO), 2020-2030 (in USD Million)
13.2.4.1.1. Active Pharmaceutical Ingredients, 2020-2030 (in USD Million)
13.2.4.1.1.1. Branded API Manufacturing, 2020-2030 (in USD Million)
13.2.4.1.1.2. Generic API Manufacturing, 2020-2030 (in USD Million)
13.2.4.1.2. Finished Dosage Formulations (FDF), 2020-2030 (in USD Million)
13.2.4.1.2.1. Solid Dosage, 2020-2030 (in USD Million)
13.2.4.1.2.2. Oral Liquids, 2020-2030 (in USD Million)
13.2.4.1.2.3. Parenteral/Injectables, 2020-2030 (in USD Million)
13.2.4.1.2.4. Other FDFs, 2020-2030 (in USD Million)
13.2.4.1.3. Secondary Packaging, 2020-2030 (in USD Million)
13.2.4.2. Pharmaceutical Contract Research Organization (CRO), 2020-2030 (in USD Million)
13.2.4.2.1. CRO for Pre-clinical Development, 2020-2030 (in USD Million)
13.2.4.2.1.1. CRO for Phase I Trials, 2020-2030 (in USD Million)
13.2.4.2.1.2. CRO for Phase II Trials, 2020-2030 (in USD Million)
13.2.4.2.1.3. CRO for Phase III Trials, 2020-2030 (in USD Million)
13.2.4.2.1.4. CRO for Phase IV Trials, 2020-2030 (in USD Million)
13.2.4.2.2. Laboratory Services, 2020-2030 (in USD Million)
13.2.4.2.3. Consulting Services, 2020-2030 (in USD Million)
13.2.4.2.4. Data Management Services, 2020-2030 (in USD Million)
14.United Kingdom Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market
14.1. Market Overview – Market Size (2020–2030)
14.2. Market segmentation by:
14.2.1. Category
14.2.2. Therapeutic Application
14.2.3. End-user
14.2.4. Service Type
15. France Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market
15.1. Market Overview – Market Size (2020–2030)
15.2. Market segmentation by:
15.2.1. Category
15.2.2. Therapeutic Application
15.2.3. End-user
15.2.4. Service Type
16.Italy Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market
16.1. Market Overview – Market Size (2020–2030)
16.2. Market segmentation by:
16.2.1. Category
16.2.2. Therapeutic Application
16.2.3. End-user
16.2.4. Service Type
17. Spain Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market
17.1. Market Overview – Market Size (2020–2030)
17.2. Market segmentation by:
17.2.1. Category
17.2.2. Therapeutic Application
17.2.3. End-user
17.2.4. Service Type
18.Rest of Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market
18.1. Market Overview – Market Size (2020–2030)
18.2. Market segmentation by:
18.2.1. Category
18.2.2. Therapeutic Application
18.2.3. End-user
18.2.4. Service Type
Please enter your personal details below
- Hangzhou Tigermed Consulting Co., Ltd
- ICON plc
- IQVIA Inc.
- LSK Global Pharma Services Co., Ltd.
- Parexel International Corporation
- PPD Inc.
- Almac Group
- Quanticate International Limited
- Samsung Biologics
- Syneos Health
- Wuxi Apptec Co., Ltd.
- Delpharm Holding
- Evonik Industries AG
- Siegfried Holding AG
- Aenova Group
- Baxter International, Inc.
- Boehringer Ingelheim International GmbH
- Catalent, Inc.
- Famar Group
- Jubilant Pharmova Limited
- Lonza
- CMIC HOLDINGS Co., LTD.
- Labcorp Drug Development
- Thermo Fisher Scientific Inc.
- Pfizer Inc.
- Recipharm AB
- Vetter Pharma-Fertigung GmbH & Co. KG
- Charles River Laboratories International, Inc.
